Cryosite (ASX:CTE) Accumulated Depreciation: A$-6.25 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:CTE Cryosite Ltd ASX:CTE
68 GF Score
Price A$1.25
GF Value A$1.01
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Cryosite Accumulated Depreciation?

Cryosite ASX:CTE 68 Accumulated Depreciation is A$-6.25 Mil as of Jun. 2026. GuruFocus rates ASX:CTE with a GF Score™ of 68/100 and a GF Value™ of A$1.01 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Cryosite's quarterly accumulated depreciation declined from Jun. 2025 (A$-5.58 Mil) to Dec. 2025 (A$0.00 Mil) but then increased from Dec. 2025 (A$0.00 Mil) to Jun. 2026 (A$-6.25 Mil).

Cryosite's annual accumulated depreciation increased from Jun. 2024 (A$-4.76 Mil) to Jun. 2025 (A$-5.58 Mil) and increased from Jun. 2025 (A$-5.58 Mil) to Jun. 2026 (A$-6.25 Mil).

Cryosite Accumulated Depreciation Related Terms

Cryosite Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for Cryosite's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cryosite Accumulated Depreciation Chart

Cryosite Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Accumulated Depreciation
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.35 -4.15 -4.76 -5.58 -6.25

Cryosite Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.76 0.00 -5.58 0.00 -6.25
ASX:CTE
68GF Score
Cryosite Ltd ASX:CTE
Accumulated Depreciation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cryosite Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of A$-6.25 Mil mean?
Cryosite (ASX:CTE) has a Accumulated Depreciation of A$-6.25 Mil as of Jun. 2026. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Cryosite and its competitors.
Is Cryosite's Accumulated Depreciation too high?
Cryosite's current Accumulated Depreciation is A$-6.25 Mil. Overall, Cryosite has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cryosite's Accumulated Depreciation compare to TMO and DHR?
Cryosite's Accumulated Depreciation of A$-6.25 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Medical Diagnostics & Research company?
A good Accumulated Depreciation depends on the Medical Diagnostics & Research industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Cryosite and its competitors. Cryosite's current Accumulated Depreciation is A$-6.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryosite stock overvalued right now?
Based on GuruFocus' analysis, Cryosite (ASX:CTE) is currently considered Modestly Overvalued. The stock's GF Value™ is A$1.01, compared to a current price of A$1.25 — trading 23.8% above its estimated fair value. The current Accumulated Depreciation is A$-6.25 Mil. Cryosite's overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For Cryosite (ASX:CTE), the current Accumulated Depreciation is A$-6.25 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cryosite (ASX:CTE) Overvalued in 2026?

Based on GuruFocus' analysis, Cryosite stock appears to be overvalued. The current stock price of A$1.25 is trading 23.8% above its estimated GF Value™ of A$1.01. GuruFocus considers Cryosite to be Modestly Overvalued.

Key valuation signals for ASX:CTE:

  • Accumulated Depreciation: A$-6.25 Mil
  • GF Value™: A$1.01 vs. price of A$1.25 (23.8% above fair value)
  • GF Score™: 68/100 with 6 warning signs

No single metric tells the full story. See the ASX:CTE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cryosite Business Description

Address 13a Ferndell Street, South Granville, Sydney, NSW, AUS, 2142
Cryosite Ltd provides an integrated clinical trial logistics service, biological storage and sample management service, including the storage of cord blood stem cells for private use. It supports a diverse portfolio of materials, including Good Manufacturing Practice (GMP) clinical trial products, Australian Register of Therapeutic Goods (ARTG) approved medicines, biologics, Research and Development materials, and medical devices, among others. The group's operating segments are: Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord blood. The majority of its revenue is generated from the Ambient, cold, and frozen segment, which provides storage and distribution of small-molecule drugs and related products requiring ambient, refrigerated, or frozen conditions.
68GF Score

Get the complete analysis for ASX:CTE

Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.25
Price
A$1.01
GF Value